Clinical Trial Update: Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of 90Y-Clivatuzumab Tetraxetan + Gemcitabine versus placebo + Gemcitabine in metastatic pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 90Y-Clivatuzumab Tetraxetan (null)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Gilead Sciences | Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer | Phase 3 | Status: TERMINATED